The Vitreomacular Interface in Diabetic Retinopathy

Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Agarwal, Rachel Gelman, Claudia Prospero Ponce, William Stevenson, John B. Christoforidis
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2015/392983
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568080487677952
author Daniel Agarwal
Rachel Gelman
Claudia Prospero Ponce
William Stevenson
John B. Christoforidis
author_facet Daniel Agarwal
Rachel Gelman
Claudia Prospero Ponce
William Stevenson
John B. Christoforidis
author_sort Daniel Agarwal
collection DOAJ
description Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.
format Article
id doaj-art-667201a431604289936342d33894b403
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-667201a431604289936342d33894b4032025-02-03T00:59:50ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/392983392983The Vitreomacular Interface in Diabetic RetinopathyDaniel Agarwal0Rachel Gelman1Claudia Prospero Ponce2William Stevenson3John B. Christoforidis4Department of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADepartment of Ophthalmology, University of Arizona Medical Center, Tucson, AZ 85711, USADiabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.http://dx.doi.org/10.1155/2015/392983
spellingShingle Daniel Agarwal
Rachel Gelman
Claudia Prospero Ponce
William Stevenson
John B. Christoforidis
The Vitreomacular Interface in Diabetic Retinopathy
Journal of Ophthalmology
title The Vitreomacular Interface in Diabetic Retinopathy
title_full The Vitreomacular Interface in Diabetic Retinopathy
title_fullStr The Vitreomacular Interface in Diabetic Retinopathy
title_full_unstemmed The Vitreomacular Interface in Diabetic Retinopathy
title_short The Vitreomacular Interface in Diabetic Retinopathy
title_sort vitreomacular interface in diabetic retinopathy
url http://dx.doi.org/10.1155/2015/392983
work_keys_str_mv AT danielagarwal thevitreomacularinterfaceindiabeticretinopathy
AT rachelgelman thevitreomacularinterfaceindiabeticretinopathy
AT claudiaprosperoponce thevitreomacularinterfaceindiabeticretinopathy
AT williamstevenson thevitreomacularinterfaceindiabeticretinopathy
AT johnbchristoforidis thevitreomacularinterfaceindiabeticretinopathy
AT danielagarwal vitreomacularinterfaceindiabeticretinopathy
AT rachelgelman vitreomacularinterfaceindiabeticretinopathy
AT claudiaprosperoponce vitreomacularinterfaceindiabeticretinopathy
AT williamstevenson vitreomacularinterfaceindiabeticretinopathy
AT johnbchristoforidis vitreomacularinterfaceindiabeticretinopathy